Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B‐cell lymphoma in the rituximab era

2021 ◽  
Author(s):  
Qingpei Guan ◽  
Yuheng Hong ◽  
Ge Hu ◽  
Qiqi Zhou ◽  
Lanfang Li ◽  
...  
Keyword(s):  
B Cell ◽  
Clinical Benefit ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Waldeyer’S Ring ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP immunochemotherapy

2018 ◽  
Vol 74 ◽  
pp. 80-85
Author(s):  
Chunyan Li ◽  
Xuejun Ma ◽  
Ziqiang Pan ◽  
Fangfang Lv ◽  
Zuguang Xia ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Waldeyer’S Ring ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study

2012 ◽  
Vol 23 (12) ◽  
pp. 3143-3151 ◽  
Author(s):  
L. de Leval ◽  
C. Bonnet ◽  
C. Copie-Bergman ◽  
L. Seidel ◽  
M. Baia ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Clinicopathologic Features ◽  
Waldeyer’S Ring ◽  
Large B Cell Lymphoma ◽  
Gela Study ◽  
Large B Cell

Clinical characteristics and prognosis of primary Waldeyer's ring and lymph node diffuse large B-cell lymphoma in the rituximab era

2017 ◽  
Vol 60 ◽  
pp. 89-93 ◽  
Author(s):  
Xiao-mei Jing ◽  
Jing-rui Yu ◽  
Yang-kun Luo ◽  
Shi-chuan Zhang ◽  
Ji-feng Liu ◽  
...  
Keyword(s):  
Lymph Node ◽  
B Cell ◽  
Clinical Characteristics ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Waldeyer’S Ring ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Prognostic value of Waldeyer’s ring involvement of diffuse large B-cell lymphoma treated with R-CHOP

2013 ◽  
Vol 97 (3) ◽  
pp. 397-402 ◽  
Author(s):  
Min-Young Oh ◽  
Joo-Seop Chung ◽  
Moo-Kon Song ◽  
Ho-Jin Shin ◽  
Ho-Sup Lee ◽  
...  
Keyword(s):  
B Cell ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Waldeyer’S Ring ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals IRF4-Rearranged Large B-Cell Lymphoma on Waldeyer’s Ring: A Case Report

2020 ◽  
Vol 37 (4) ◽  
pp. 292-294
Author(s):  
Deram Büyüktaş ◽  
Serdar Örnek ◽  
Fatma Tokat ◽  
Tülay Tecimer ◽  
Burhan Ferhanoğlu
Keyword(s):  
Case Report ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Waldeyer’S Ring ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy

2012 ◽  
Vol 54 (1) ◽  
pp. 62-68 ◽  
Author(s):  
Michael Mian ◽  
Andrés J. M. Ferreri ◽  
Andrea Rossi ◽  
Annarita Conconi ◽  
Richard Tsang ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Early Stage ◽  
B Cell Lymphoma ◽  
Waldeyer’S Ring ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Fostamatinib for the treatment of diffuse large B-cell lymphoma.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e20067-e20067
Author(s):  
Hendrik-Tobias Arkenau ◽  
Anna Patrikidou ◽  
Ian Flinn ◽  
Jonas C. Hylton ◽  
Sandra Tong ◽  
...  
Keyword(s):  
Partial Response ◽  
B Cell ◽  
Clinical Benefit ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Complete Response ◽  
Intermediate Cell ◽  
Cell Of Origin ◽  
Large B Cell Lymphoma ◽  
Large B Cell

e20067 Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive and common form of non-Hodgkin’s lymphoma, characterized by marked genetic heterogeneity. The disease is difficult to treat, and patients with relapsed/refractory DLBCL often have poor outcomes. Some subsets of DLBCL have an increased reliance on B-cell receptor (BCR) activity. Spleen tyrosine kinase (SYK) is a signaling molecule essential for BCR activation. Fostamatinib, an oral SYK inhibitor, was evaluated for treatment of relapsed/refractory DLBCL in a phase 2 randomized, placebo-controlled trial1(NCT01499303), and 9 patients had clinical benefit (1 complete response, 1 partial response, and 7 stable disease). The patients with clinical benefit from fostamatinib treatment had DLBCL of germinal center B-cell (GCB) or intermediate cell of origin. We present the clinical outcomes of 2 patients from this trial who continued to benefit from fostamatinib treatment for over 6 years. Methods: Medical records for the 2 patients were retrospectively reviewed for dose regimen, clinical response, and safety data. Results: Patient A, a 63-year-old male patient with DLBCL of GCB origin, had been diagnosed with follicular lymphoma in 1996, transformation in 2002. He had undergone 1 line of treatment for follicular lymphoma and 5 treatments for DLBCL prior to fostamatinib treatment. He started fostamatinib at 100mg BID in Dec 2012, which was reduced to 100mg daily in Apr 2013, and patient continues at 100 mg QD. Patient A has maintained a complete response (CR) for > 5 years. An isolated infra-centimetric suspicious lesion was noted in Patient A in May 2019, which is stable as of January 2020 with a progressive decrease of metabolic activity. Patient B, a male with DLBCL of an intermediate cell of origin, was 69 years old at baseline with 2 DLBCL treatments prior to fostamatinib treatment since his diagnosis in Aug 2012. He started fostamatinib in May 2013 at 200 mg BID with no dose changes over the last 7 years. Patient B had a partial response (PR) per Chesson criteria since December 2014, with a sustained improved metabolic response continuing since ( > 6 years), with all but a single metastatic site no longer visible. The only serious adverse event in these 2 patients was a ventricular fibrillation and grade 4 cardiac arrest at Day 90 in Patient B, necessitating defibrillation insertion. This was deemed unrelated to treatment and resolved. Conclusions: Fostamatinib may provide durable benefit to a small subset of patients with relapsed/refractory DLBCL. 1. Flinn, I.W., et al., Eur J. Cancer 2016; 54:11-17

Sign in / Sign up

Export Citation Format

Share Document